l 368899 has been researched along with dronabinol in 1 studies
| Studies (l 368899) | Trials (l 368899) | Recent Studies (post-2010) (l 368899) | Studies (dronabinol) | Trials (dronabinol) | Recent Studies (post-2010) (dronabinol) |
|---|---|---|---|---|---|
| 46 | 0 | 30 | 8,307 | 785 | 3,094 |
| Protein | Taxonomy | l 368899 (IC50) | dronabinol (IC50) |
|---|---|---|---|
| Cannabinoid receptor 1 | Rattus norvegicus (Norway rat) | 0.218 | |
| Cannabinoid receptor 1 | Homo sapiens (human) | 0.0028 | |
| Cannabinoid receptor 2 | Homo sapiens (human) | 0.0095 | |
| Cannabinoid receptor 2 | Rattus norvegicus (Norway rat) | 0.218 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bowen, RC; Cui, SS; Gu, GB; Hannesson, DK; Yu, PH; Zhang, X | 1 |
1 other study(ies) available for l 368899 and dronabinol
| Article | Year |
|---|---|
Prevention of cannabinoid withdrawal syndrome by lithium: involvement of oxytocinergic neuronal activation.
Topics: Animals; Behavior, Animal; Brain; Camphanes; Cannabinoids; Densitometry; Dose-Response Relationship, Drug; Dronabinol; Immunohistochemistry; In Situ Hybridization; Lithium; Male; Morpholines; Neurons; Oxytocin; Piperazines; Proto-Oncogene Proteins c-fos; Pyrazoles; Radioimmunoassay; Rats; Rats, Long-Evans; Receptors, Cannabinoid; Receptors, Drug; Receptors, Oxytocin; Substance Withdrawal Syndrome | 2001 |